University of Tennessee Graduate School of Medicine Amyloidosis and Cancer Theranostics Program | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to Places / Academic & Health Care Centers
University Of Tennessee Graduate School Of Medicine Amyloidosis And Cancer Theranostics Program

University of Tennessee Graduate School of Medicine Amyloidosis and Cancer Theranostics Program

1924 Alcoa Highway
Knoxville, Tennessee, United States
Phone   Web  

The history of the Amyloidosis and Cancer Theranostics Program (ACTP) is rooted in the study of light chain (AL) amyloidosis and the development of novel agents for the study, detection and treatment of this disease. In recent years, the Program has both extended its horizons to encompass all amyloid-related disorders and some specific malignancies, and focused principally on peptides as biological agents for targeting these diseases as a means of detection and treatment. 

The major thrust of the ACTP is developing, characterizing and translating novel synthetic peptides into the clinic for the non-invasive imaging of amyloidosis in patients by using PET/CT and SPECT/CT. In addition, they are developing novel strategies for the treatment of amyloidosis by exploiting the exquisite targeting abilities of the synthetic peptides.

In collaboration with colleagues at the University of Tennessee and Oak Ridge National Laboratory, they are assessing the ability of synthetic peptides to inhibit cell infection by cytomegalovirus, a major cause of childhood deafness and mental retardation. Finally, work with the University of Tennessee Medical Center and UT College of Veterinary Medicine has led to the discovery that peptides can be used to target metastatic melanoma as well as certain carcinomas.

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close